New Approaches to Measuring Value in Oncology Therapy
Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
5 Things to Know About the Oral GLP-1 Era
4
Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention
5
